Urokinase anchors uPAR to the actin cytoskeleton

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 9, 2004, Pages 2967-2977

  Bernstein, Audrey M ^a   Greenberg, Roseanne S ^a   Taliana, Lavinia ^a   Masur, Sandra K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYTOCHALASIN D; F ACTIN; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CORNEA; CORNEA INJURY; FIBROBLAST; FLUORESCENCE MICROSCOPY; FOCAL ADHESION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; STRESS FIBER;

ACTINS; ADULT; CELL MEMBRANE; CELL MOVEMENT; CELLS, CULTURED; CORNEA; CYTOCHALASIN D; CYTOSKELETON; FIBROBLASTS; FOCAL ADHESIONS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, CELL SURFACE; STAINING AND LABELING; TISSUE DISTRIBUTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 4344685552     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0030     Document Type: Article

References (48)

1. Weimar V. The transformation of corneal stromal cells to fibroblasts in corneal wound healing. Am J Ophthalmol. 1957;44:173-182.
2. Nakayasu K. Stromal changes following removal of epithelium in rat cornea. Jpn J Ophthalmol. 1988;32:113-125.
3. Twining SS, Wilson PM, Ngamkitidechakul C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1alpha and -1beta. Biochem J. 1999;339:705-712.
4. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer (review). Adv Cancer Res. 1985;44:139-266.
5. Vaheri A, Stephens RW, Salonen EM, Pollanen J, Tapiovaara H. Plasminogen activation at the cell surface-matrix interface (review). Cell Differ Dev. 1990;32:255-262.
6. Tang H, Kerins D, Hao Q, Inagami T, Vaughan D. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem. 1998;273:18268-18272.
7. Dumler I, Weis A, Mayboroda O, et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol Chem. 1998;273:315-321.
8. Aguirre Ghiso J, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999;147:89-104.
9. Ploug M, Behrendt N, Lober D, Dano K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost. 1991;17:183-193.
10. Xue W, Mizukami I, Todd RF, Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997;57:1682-1689.
11. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
12. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998;188:1029-1037.
13. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J Biol Chem. 2000;275:10228-10234.
14. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase-type Plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem. 2001;276:3983-3990.
15. Tripathi RC, Tripathi BJ, Park JK. Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. Exp Eye Res. 1990;51:545-552.
16. Rabbani SA, Mazar AP, Bernier SM, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem. 1992;267:14151-14156.
17. Stoppelli MP, Tacchetti C, Cubeills MV, et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell. 1986;45: 675-684.
18. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem. 1989;264:1180-1189.
19. Mayor S, Rothberg KG, Maxfield FR. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science. 1994;264:1948-1951.
20. Myohanen HT, Stephens RW, Hedman K, et al. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem. 1993;41:1291-1301.
21. Wilcox-Adelman SA, Wilkins-Port CE, McKeown-Longo PJ. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell Adhes Commun. 2000;7:477-490.
22. Baker MS, Liang XM, Doe WF. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA). Biochim Biophys Acta. 1992; 1117:143-152.
23. Slepian MJ, Massia SP, Dehdashti B, Fritz A, Whitesell L. Beta3-integrins rather than betal-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation. 1998;97:1818-1827.
24. Hoyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267:18224-18229.
25. Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem. 1992;267:13617-13622.
26. Cejkova J, Lojda Z. The appearance of active plasminogen activator of urokinase type (u-PA) in the rabbit anterior eye segment irradiated by UVB rays: a histochemical and biochemical study. Acta Histochem. 1995;97:257-262.
27. Cejkova J. The appearance and possible role of plasminogen activator of urokinase type (u-PA) activity in the cornea related to soft contact lens wear in rabbits. Doc Ophthalmol. 1998;95:165-179.
28. Watanabe M, Yano W, Kondo S, et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci. 2003;44:3332-3338.
29. Maxfield FR, Mayor S. Cell surface dynamics of GPI-anchored proteins (review). Adv Exp Med Biol. 1997;419:355-364.
30. Fujimoto T. GPI-anchored proteins, glycosphingolipids, and sphingomyelin are sequestered to caveolae only after crosslinking. J Histochem Cytochem. 1996;44:929-941.
31. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol. 1998;141:929-942.
32. Kindzelskii AL, Laska ZO, Todd RF III, Petty HR, Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2′ CD11b/CD18) during neutrophil polarization. J Immunol. 1996;156:297-309.
33. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71:411-421.
34. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell. 2001;12:1467-1479.
35. Kanse SM, Benzakour O, Kanthou C, Kost C, Lijnen HR, Preissner KT. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol. 1997;17:2848-2854.
36. Mukhina S, Stepanova V, Traktouev D, et al. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain: characterization of interactions and contribution to chemotaxis. J Biol Chem. 2000;275:16450-16458.
37. Koopman JL, Slomp J, de Bart AC, Quax PH, Verheijen JH, Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J Biol Chem. 1998;273:33267-33272.
38. Deindl E, Ziegelhoffer T, Kanse SM, et al. Receptor-independent role of the urokinase-type plasminogen activator during arteriogenesis. FASEBJ. 2003;17:1174-1176.
39. Dumler I, Kopmann A, Wagne RK, et al. Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J Biol Chem. 1999;274:24059-20565.
40. Dumler I, Kopmann A, Weis A, et al. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:290-297.
41. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002;4:E83-E90.
42. Fujiwara T, Ritchie K, Murakoshi H, Jacobson K, Kusumi A. Phospholipids undergo hop diffusion in compartmentalized cell membrane. J Cell Biol. 2002;157:1071-1081.
43. Edidin M, Kuo SC, Sheetz MP. Lateral movements of membrane glycoproteins restricted by dynamic cytoplasmic barriers. Science. 1991;254:1379-1382.
44. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994; 269:14746-14750.
45. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997;420:79-85.
46. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett. 2000;470:40-46.
47. Kiian I, Tkachuk N, Haller H, Dumler I. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb Haemost. 2003;89:904-914.
48. Køller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol. 2001;152: 1145-1157.